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Abstract: Although the antibody response induced by primary vaccination with Fel-O-Vax® FIV 
(three doses, 2–4 weeks apart) is well described, the antibody response induced by annual vaccina-
tion with Fel-O-Vax® FIV (single dose every 12 months after primary vaccination) and how it com-
pares to the primary antibody response has not been studied. Residual blood samples from a pri-
mary FIV vaccination study (n = 11), and blood samples from cats given an annual FIV vaccination 
(n = 10), were utilized. Samples from all 21 cats were tested with a commercially available PCR 
assay (FIV RealPCRTM), an anti-p24 microsphere immunoassay (MIA), an anti-FIV transmembrane 
(TM; gp40) peptide ELISA, and a range of commercially available point-of-care (PoC) FIV antibody 
kits. PCR testing confirmed all 21 cats to be FIV-uninfected for the duration of this study. Results 
from MIA and ELISA testing showed that both vaccination regimes induced significant antibody 
responses against p24 and gp40, and both anti-p24 and anti-gp40 antibodies were variably present 
12 months after FIV vaccination. The magnitude of the antibody response against both p24 and 
gp40 was significantly higher in the primary FIV vaccination group than in the annual FIV vaccina-
tion group. The differences in prime versus recall post-vaccinal antibody levels correlated with FIV 
PoC kit performance. Two FIV PoC kits that detect antibodies against gp40, namely Witness® and 
Anigen Rapid®, showed 100% specificity in cats recently administered an annual FIV vaccination, 
demonstrating that they can be used to accurately distinguish vaccination and infection in annually 
vaccinated cats. A third FIV PoC kit, SNAP® Combo, had 0% specificity in annually FIV-vaccinated 
cats, and should not be used in any cat with a possible history of FIV vaccination. This study out-
lines the antibody response to inactivated Fel-O-Vax® FIV whole-virus vaccine, and demonstrates 
how best to diagnose FIV infection in jurisdictions where FIV vaccination is practiced. 
Keywords: Australia; capsid protein; diagnosis; FIV; gp40; immunity; lentivirus; p24; transmem-
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Feline immunodeficiency virus (FIV) is a Lentivirus that infects domestic and feral 
cats (Felis silvestris catus) in addition to many non-domestic felids (e.g., lions, pumas and 
bobcats) and African hyenids [1,2]. Since its discovery in 1986 [3], FIV infection has been 
used as an animal model for human immunodeficiency virus (HIV-1) infection, especially 
in relation to the development of a HIV-1 vaccine [4–8]. As with FIV vaccination in cats, 
a critical consideration for the development and uptake of an effective HIV-1 vaccine will 
be the ability to quickly and accurately differentiate HIV-1-vaccinated and HIV-1-infected 
people using point-of-care (PoC) antibody test kits [9–13]. 
The culmination of a sustained FIV research effort was the release of a dual-subtype 
(FIV-A and FIV-D) formalin-inactivated whole-virus (IWV)/inactivated whole-cell (IWC) 
FIV vaccine (Fel-O-Vax® FIV; Boehringer Ingelheim, Fort Dodge, IA, USA) in USA (2002), 
Canada (2003), Australia and New Zealand (2004), and Japan (2008) [14]. In all jurisdic-
tions where it is still available (Australia, New Zealand and Japan), Fel-O-Vax® FIV is 
licensed as requiring a primary course of three vaccinations, administered 2–4 weeks 
apart, followed by single re-vaccination every 12 months to ‘boost’ immunity. The release 
of this vaccine was initially met with resistance from some veterinarians since PoC test 
kits that could differentiate FIV-vaccinated and FIV-infected animals had not been iden-
tified, thereby creating a ‘diagnostic dilemma’ [15,16]. False-positive FIV test results in 
uninfected FIV-vaccinated cats have particularly serious implications in shelters where 
an incorrect FIV test result can lead to euthanasia [16,17]. Consequently, the World Small 
Animal Veterinary Association (WSAVA) Vaccination Guidelines in 2010 listed the Fel-
O-Vax® FIV vaccine as ‘Not Recommended’ [18]. 
A breakthrough in FIV diagnostics occurred when it was reported that two commer-
cially available FIV PoC antibody test kits (Witness®, Zoetis Animal Health, Lyon, France; 
and Anigen Rapid®, BioNote, Gyeonggi-do, Korea) could accurately differentiate FIV-
vaccinated and FIV-infected cats, using whole blood or saliva [11,19]. Similar findings 
were reported the following year using plasma as a diagnostic sample [20]. Additional 
testing determined that false-positive results with Witness® and Anigen Rapid® can occur 
in cats that have received a primary course of FIV vaccination within the preceding six 
months, and in these cats other discriminatory testing such as virus isolation should be 
performed [21]. A third FIV PoC antibody test kit (SNAP® Combo, IDEXX Laboratories, 
Westbrook, ME, USA) does not differentiate vaccinated and infected cats, irrespective of 
how recently FIV vaccination has occurred, with false-positive results produced in more 
than 98% of vaccinated cats including some cats that had not been vaccinated for seven 
years [11,20]. The resolution of the FIV ‘diagnostic dilemma’ by using specific FIV PoC 
antibody kits played a role in the WSAVA Vaccination Guidelines re-classifying Fel-O-
Vax® FIV from ‘Not Recommended’ to ‘Non-Core’ in 2015 [22]. 
No studies have examined serial samples collected from cats after annual FIV vac-
cination to measure antibody response and evaluate the performance of FIV PoC antibody 
kits over time. The aim of the present study was to monitor the antibody response in cats 
recently administered an annual FIV vaccination, using both semi-quantitative FIV PoC 
test kits and quantitative laboratory assays, and to compare anti-FIV antibody responses 
induced by primary FIV vaccination vs. annual FIV vaccination. 
2. Materials and Methods 
2.1. Sample Populations 
For the primary FIV vaccination cohort (n = 11), residual samples from client-owned 
kittens/cats were utilized [21]. Briefly, four kittens (<6 months of age) and seven cats (>6 
months of age) were recruited, including six males and five females, ranging in age from 
three months to 7.6 years (median age 1.5 years; interquartile range [IQR] 0.5–2.6 years). 
Ten cats were non-pedigreed and one was a Ragdoll. All animals were neutered. For the 
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present study, day 0 was considered the day that the kitten/cat presented to the veterinary 
clinic for the first dose of a primary course of Fel-O-Vax® FIV vaccination. 
For the annual FIV vaccination cohort (n = 10), client-owned cats were recruited in-
cluding eight males and two females. The cats ranged in age from 1.3 years to 10.8 years 
(median age 6.0 years; IQR 2.6–8.9 years). All ten cats were non-pedigreed and neutered. 
Day 0 of this study was considered the day that the cat presented to the clinic for annual 
Fel-O-Vax® FIV vaccination. 
2.2. Vaccination 
Fel-O-Vax® FIV was administered subcutaneously into the dorsal interscapular space 
in all animals. None of the animals recruited for the primary vaccination study had been 
previously vaccinated against FIV. In accordance with the vaccine manufacturer’s guide-
lines, kittens/cats were vaccinated with Fel-O-Vax® FIV on days 0, 28 and 56. All kit-
tens/cats were kept with their owners for the duration of this study, and owners were 
encouraged to confine their cats indoors for two weeks after the final FIV vaccination to 
avoid possible FIV exposure prior to an immunological vaccination response occurring. 
In the annual vaccination study, FIV vaccination histories for recruited cats were ex-
tracted from medical records and interrogated to ensure compliance with the vaccine 
manufacturer’s guidelines. Six of the ten cats had received their first primary FIV vaccina-
tion prior to six months of age and therefore did not have pre-vaccination FIV antibody 
testing performed; the remaining four cats received their first FIV vaccination at an age 
older than six months of age and had tested FIV-negative with a SNAP® Combo PoC kit 
prior to FIV vaccination. All primary and annual FIV vaccinations had been administered 
in accordance with the vaccine manufacturer’s guidelines. The median number of annual 
FIV vaccinations that had been given prior to sampling was two (range 0–7, IQR 1–2.3). 
The median time since the last annual FIV vaccination was 362 days (range 319–396 days; 
IQR 324–372 days). All cats were kept with their owners for the duration of this study. 
Cats in both the primary FIV and annual FIV vaccination groups were concurrently 
vaccinated with a core vaccine containing feline parvovirus virus (FPV), feline herpesvi-
rus type-1 (FHV-1) and feline calicivirus (FCV) antigens (‘F3′), or FPV, FHV-1, FCV, feline 
leukemia virus (FeLV) and Chlamydia felis antigens (‘F5′). Core vaccines were adminis-
tered subcutaneously into the dorsal interscapular space, a few centimeters away from 
the site of FIV vaccine administration, in all animals. F3 vaccines administered were either 
inactivated (i.e., adjuvanted; Fel-O-Vax® 3; Boehringer Ingelheim, Fort Dodge, IA, USA) 
or modified-live formulations (Feligen® RCP; Virbac Animal Health, Milperra, NSW, 
Australia), while the F5 vaccine administered is only available as an inactivated vaccine 
(Fel-O-Vax® 5; Boehringer Ingelheim, Fort Dodge, IA, USA). The core vaccine dosing re-
gime for kittens was three F3 vaccines administered one month apart, while the core vac-
cine dosing regime for adult cats was a single F3 or F5 annual booster dose. Supplemen-
tary Table S1 contains the details of core vaccines administered to each animal in the pre-
sent study. 
2.3. Determination of FIV Infection Status 
Cats were tested for anti-FIV antibodies on day 0 using EDTA whole blood and com-
mercially available PoC kits (primary FIV vaccination study—Witness®; Anigen Rapid®; 
SNAP® Combo; and VETSCAN® Rapid, Abaxis, Union City, CA, USA; annual FIV vac-
cination study—Witness® and Anigen Rapid®). PCR testing was also performed on day 0 
in both studies using a commercially available real-time PCR assay, and on the final day 
of sampling (day 238 for the primary vaccination study, day 42 for the annual vaccination 
study; FIV RealPCRTM, IDEXX Laboratories, East Brisbane, Queensland, Australia) (Table 
1). 
Witness® and Anigen Rapid® are immunochromatography test kits targeting enve-
lope transmembrane glycoprotein gp40 for detection of FIV infection with sensitivities 
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(Se) of 100%/100%, and specificities (Sp) of 98%/100%, respectively, under Australian con-
ditions [11]. SNAP® Combo is a lateral flow enzyme-linked immunosorbent assay (ELISA) 
kit that in Australia detects antibodies against matrix protein p15 and capsid protein p24, 
and in Europe detects antibodies against p15, p24 and gp40 [11]. In Australia, SNAP® 
Combo had a Se/Sp of 100%/64% in a cohort that included 33% FIV-vaccinated cats [11]. 
In Europe, SNAP® Combo had a Se/Sp of 100%/99.6% in a cohort that did not include any 
FIV-vaccinated cats [23]. VETSCAN® Rapid is an immunochromatography kit that detects 
antibodies against p24 and has a reported Se/Sp in FIV-unvaccinated cats of 92%/99% 
[21,24]. FIV RealPCRTM targets a conserved region of the gag gene and has a reported Se/Sp 
of 92%/99% in Australia [11]. Results from FIV RealPCRTM testing are not affected by Fel-
O-Vax® FIV vaccination [11]. 
Cats were considered FIV-uninfected at the start of this study if they tested antibody 
negative with all PoC kits and PCR negative on day 0, and FIV-uninfected at the end of 
this study if they tested PCR negative at the final sampling (day 238 and day 42, respec-
tively). All 21 cats were determined to be FIV-uninfected for the duration of this study. 
2.4. Sampling Procedure 
Kittens/cats recruited for the primary vaccination study were sampled fortnightly 
until four weeks after the third primary FIV vaccination (i.e., days 0, 14, 28, 42, 56, 70 and 
84), and again six months later (day 238). Cats recruited for the annual vaccination study 
were sampled fortnightly for six weeks after vaccination (i.e., days 0, 14, 28 and 42) (Table 
1).  
Table 1. Vaccination and testing schedule for primary and annual FIV vaccination studies. FIV antibody testing included 
testing with a variety of point-of-care (PoC) antibody kits, an anti-p24 antibody microsphere immunoassay (MIA), and an 
anti-gp40 antibody ELISA. PCR testing was performed by a commercial veterinary laboratory (FIV RealPCRTM, IDEXX 
Laboratories). For MIA and ELISA testing, samples from two weeks after the third primary FIV dose were compared to 
samples from two weeks after annual FIV vaccination (i.e., day 70* vs. day 14*), and samples from four weeks after the 
third primary FIV dose were compared to samples from four weeks after annual FIV vaccination (i.e., day 84† vs. day 28†). 
Superscripts denote equivalent time points tested for primary vs. annual vaccination. Additional MIA and ELISA testing 
at other time points was performed (brackets) but not used for comparisons between vaccination groups; these results are 
included as Supplementary data. 
 Day 0 Day 14 Day 28 Day 42 Day 56 Day 70* Day 84† Day 238 
Primary vaccination study (n = 11) 
 FIV vaccination 
 PoC antibody testing 
 MIA p24 / ELISA gp40 testing 







































 Day 0 Day 14* Day 28† Day 42     
Annual vaccination study (n = 10) 
 FIV vaccination 
 PoC antibody testing 
 MIA p24 / ELISA gp40 testing 



















    
Sampling involved collecting approximately 1 mL of blood using jugular venipunc-
ture and immediately transferring the specimen to an EDTA tube. When PCR testing was 
also performed, an additional 0.5 mL of blood was collected and aliquoted into a second 
EDTA tube. Blood tubes were stored at 4 °C until required. Testing for FIV antibodies 
with PoC kits was performed within 24 h of blood collection at the recruiting veterinary 
clinic or The University of Sydney, using whole blood from the EDTA tube and according 
to the manufacturer’s instructions (with one exception; see below). Following PoC testing, 
blood tubes were centrifuged for 3 min at 12,000 g, the plasma transferred to a plain tube 
using a sterile pipette, and the plasma specimens then stored at −80 °C until required. 
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Plasma samples were transported at −20 °C to Colorado State University for anti-p24 mi-
crosphere immunoassay (MIA) testing, and at −80 °C to Veterinary Diagnostic Services 
(VDS), The University of Glasgow, for anti-gp40 ELISA testing. Samples from the annual 
vaccination study were also tested at VDS, Glasgow using European SNAP® Combo PoC 
kits. 
2.5. Evaluation of Antibodies to p24 Using a Microsphere Immunoassay (MIA) 
Plasma samples from days 0, 14*, and 28† post-final vaccination (Primary: days 0, 70* 
and 84†; Annual: days 0, 14*, and 28†) were analyzed by microsphere immunoassay (MIA) 
for evaluation of antibodies against FIV capsid protein p24 (Table 1). Superscripts denote 
equivalent time points tested for primary vs. annual vaccination. Recombinant p24 pro-
tein used for MIA analysis was synthesized as previously described [25]. MIA was per-
formed using previously established protocols involving conjugation of protein to car-
boxylated magnetic microspheres (MagPlex® Microspheres, Luminex, Austin, TX, USA) 
[25–27]. Following conjugation, microsphere concentrations were determined by hemo-
cytometer, and protein coupling confirmed by incubation of microspheres with phyco-
erythrin (PE)-conjugated detection antibodies [26]. Successful coupling was determined 
by a median fluorescence intensity (MFI) of >2000. Samples were then diluted 1:50 in as-
say buffer and incubated in duplicate with ~2500 conjugated beads per well, as described 
previously [26]. All samples were concurrently assayed with FIV-A (positive) and FIV-
naïve (negative) reference samples diluted 1:50 in assay buffer, as well as four diluent 
control wells [26]. MFI was calculated from ≥100 microspheres per well (Bio-Plex™ Man-
ager 5.0) and recorded as ‘negative fold’ (NF), where NF = (sample MFI) / (2 × negative 
control MFI). NF values were then used for statistical analyses [26,28]. All reagent con-
centrations, volumes, incubation times, positive and negative control reference samples, 
acceptable standard recovery, and data analysis were as described previously [25–27]. 
Samples from day 0 of the primary vaccination group served as FIV-unvaccinated con-
trols. Samples were considered positive if NF values were greater than the mean NF of 
FIV-unvaccinated controls × 2 Standard Deviations (SD) [29]. Insufficient volume for MIA 
testing occurred in four primary vaccination samples and four annual vaccination sam-
ples. 
2.6. Evaluation of Antibodies to gp40 Using a Laboratory ELISA 
Plasma samples from days 0, 14*, and 28† post-final vaccination (Primary: days 0, 70* 
and 84†; Annual: days 0, 14*, and 28†) were analyzed by ELISA to detect antibodies bind-
ing the FIV transmembrane (TM; gp40) peptide as described previously [21] (Table 1). A 
nine-amino acid (AA) sequence peptide (CNQNQFFCK; cysteine–asparagine–gluta-
mine–asparagine–glutamine–phenylalanine–phenylalanine–cysteine–lysine) from the 
highly conserved immunodominant TM2 domain of gp40 was used [30,31]. To the best of 
our knowledge, the Witness® kit employs a 14 AA peptide, incorporating the nine AA 
sequence used for the laboratory-based TM ELISA, as its gp40 capture antigen [11,32]. 
The composition of the gp40 capture antigen used in the Anigen Rapid® kit is unknown. 
Known positive and negative controls were included on each test plate [21]. The pos-
itive control was pooled plasma from specific pathogen-free (SPF) cats experimentally 
infected with FIV, confirmed by Western blot and virus isolation. The negative control 
was a pooled sample from FIV-uninfected SPF cats, also confirmed by Western blot and 
virus isolation. Optical density (OD) results for samples were recorded as ‘negative fold’ 
(NF), where NF = (sample OD) / (2 × negative control OD). NF values were then used for 
statistical analyses [28]. Samples from day 0 of the primary vaccination group served as 
FIV-unvaccinated controls. Samples were considered positive if NF values were greater 
than the mean NF of FIV-unvaccinated controls ×2 SD [29]. Insufficient volume for ELISA 
testing occurred in four primary vaccination samples and four annual vaccination sam-
ples. 
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2.7. ‘Positive’ and ‘False-Positive’ Terminology for Antibody Test Results 
Witness® and Anigen Rapid® are FIV antibody tests developed for the diagnosis of 
naturally acquired FIV infection by detection of antibodies to gp40. Therefore, a positive 
Witness® or Anigen Rapid® FIV result in a vaccinated/uninfected cat is reported as a ‘false-
positive’ result. The MIA and ELISA testing performed was developed for the quantifica-
tion of anti-p24 and anti-gp40 antibodies, not diagnosis of FIV infection. Therefore, a pos-
itive anti-p24 MIA or positive anti-gp40 ELISA result is reported as a ‘positive’ result. 
2.8. Ethics Approval  
Animal ethics approval for both studies was granted by The University of Sydney 
(approval number 2015/858 for the primary vaccination study; approval number 
2017/1167 for the annual vaccination study). 
2.9. Statistical Analysis  
Statistical analyses were performed using the commercially available software: Gen-
stat 18th Edition (VSN International, Hemel Hempstead, UK) and GraphPad Prism 9.0 
(La Jolla, CA, USA). Signalment data of the two vaccination cohorts were compared by 
two-sample t-testing (age) and Fisher’s exact testing (sex and breed). Antibody levels (rec-
orded as NF) within and between vaccination groups over time were compared by linear 
regression and repeated measures ANOVA using a mixed-effects model approach. Pear-
son’s correlation and logistic regression were used to compare anti-gp40 ELISA results to 
anti-gp40 PoC test results (i.e., Witness® and Anigen Rapid®), and to analyze the anti-p24 
and anti-gp40 antibody response following annual vaccination according to number of 
annual re-vaccinations received. For MIA (p24) and ELISA (gp40) testing, samples from 
two weeks after the third primary FIV dose were compared to samples from two weeks 
after annual FIV vaccination (i.e., day 70* vs. day 14*), and samples from four weeks after 
the third primary FIV dose were compared to samples from four weeks after annual FIV 
vaccination (i.e., day 84† vs. day 28†). Statistical significance was considered when p < 0.05. 
3. Results 
3.1. Sample Populations 
Kittens/cats recruited for the primary vaccination study were significantly younger 
than cats in the annual vaccination study (p = 0.005; two-sample t-test). There was no dif-
ference between vaccination groups in terms of sex and breed (p = 0.36 and 1.00, respec-
tively; Fisher’s exact tests) (Table 2). 
Table 2. Signalment data of the two vaccination cohorts. All recruited animals were neutered. IQR = interquartile range, 
M = male, F = female, P = pedigreed, and NP = non-pedigreed. See Supplementary Table 1 for individual animal data. 
Group Age (Years) Sex Breed p Value 
Primary Vaccination  0.3–7.6 
(median 1.5; IQR 0.5–2.6) 
6M, 5F 1P, 10NP p = 0.005 (age) 
p = 0.36 (sex) 
p = 1.00 (breed) 
 
Annual Vaccination 1.3–10.8 
(median 6.0; IQR 2.6–8.9) 
8M, 2F 10NP 
3.2. FIV Point-of-Care Testing (Primary Vaccination) 
Results from FIV PoC testing in both vaccination groups are shown in Table 3. All 
four PoC kits tested false-positive at different points in the primary vaccination study. 
Witness® and Anigen Rapid® produced their highest rate of false-positive results on day 
42 (two weeks after the second primary FIV vaccination; 64% and 55%, respectively), and 
were still false-positive in some cats on day 70 (two weeks after the final primary FIV 
vaccination; 55% and 36%, respectively) and day 84 (four weeks after the final primary 
FIV vaccination; 18% for both). Both kits tested negative in all cats on day 238. In total, 
6/11 cats in the primary vaccination study tested false-positive with both Witness® and 
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Anigen Rapid® at some time point, 3/11 never tested false-positive with either Witness® 
or Anigen Rapid®, 1/11 tested false-positive only with Witness® and not Anigen Rapid® 
(day 14–day 70), and 1/11 tested false-positive only with Anigen Rapid® and not Witness® 
(day 42). SNAP® Combo produced false-positive results in 100% of cats on day 28 (four 
weeks after the first primary FIV vaccination), and this result was reproduced for the du-
ration of this study. VETSCAN® Rapid produced false-positive results in 100% of cats 
between days 42 and 84, and 82% of cats on day 238. 
3.3. FIV Point-of-Care Testing (Annual Vaccination) 
Witness® and Anigen Rapid® produced negative results in all 10 cats for the duration 
of the annual vaccination study, including day 0. In contrast, 100% of cats in the annual 
vaccination study tested false-positive with SNAP® Combo on day 0, and remained false-
positive for the duration of this study (Table 3). 
Table 3. Cats in the annual FIV vaccine study did not elicit positive results on Witness® or Anigen Rapid® point-of-care 
(PoC) test kits. Primary vaccination table results have been taken from Westman et al. (2017) [21]. All PoC testing was 
performed using whole blood, except for testing with SNAP® Combo in the annual vaccination study which was per-
formed using plasma. There was insufficient plasma from ten samples in the annual vaccination study to perform FIV 
testing with SNAP® Combo. VACC = vaccination with Fel-O-Vax® FIV. NP = not performed. The numerator indicates the 
number of false-positive test results. 
 Day 0 Day 14 Day 28 Day 42 Day 56 Day 70 Day 84 Day 238 
Primary vaccination study (n = 11) 
 Witness® 
 Anigen Rapid® 
 SNAP® Combo 
 VETSCAN® Rapid 














































 Day 0 Day 14 Day 28 Day 42     
Annual vaccination study (n = 10) 
 Witness® 
 Anigen Rapid® 
 SNAP® Combo 
 VETSCAN® Rapid 























    
3.4. Antibodies to FIV p24 with MIA Testing 
Results from MIA testing of plasma samples from days 0, 14*, and 28† after final vac-
cination (Primary: days 0, 70* and 84†; Annual: days 0, 14* and 28†) to detect anti-p24 an-
tibodies are presented in Figure 1 and Supplementary Table S2. Compared to day 0, in-
creased levels of anti-p24 antibodies were detected in both vaccination groups on days 
14* and 28†, indicating that both primary and annual FIV vaccination induced a significant 
anti-p24 antibody response (Primary: p < 0.0001, Annual: p = 0.012; mixed-effects analy-
sis). The overall magnitude of the anti-p24 antibody response was 3.0× higher at day 14* 
and 2.4× higher at day 28† in the primary vaccination group compared to the annual vac-
cination group (treatment, p < 0.0001), as evidenced by increased levels of anti-p24 anti-
bodies in primary vaccinated animals over time (interaction, p < 0.0001) and at individual 
time points (days 14* and 28†: p < 0.0001) (mixed-effects analysis). Anti-p24 antibodies 
were detected in 6/10 cats in the annual vaccination group on day 0, indicating that anti-
bodies persisted for at least 12 months after previous vaccination in a subset of cats (Table 
4). Despite this finding, post hoc analysis revealed there was no significant difference be-
tween anti-p24 antibody levels in primary vs. annually vaccinated cats on day 0 (p = 0.56, 
Šídák’s multiple comparisons test). 




Figure 1. Anti-p24 antibody response from primary FIV vaccination was higher than annual FIV 
re-vaccination. Microsphere immunoassay (MIA) detected increases in anti-p24 antibodies over 
time in both primary and annual vaccination groups (Primary: p < 0.0001; Annual: p = 0.012; blue 
and red bars below the box plots, respectively; mixed-effects analysis). Anti-p24 antibodies dif-
fered significantly over time between groups (interaction, p < 0.0001) and at individual time points 
following vaccination (p < 0.0001, where the black bars joining the box plots indicate the analysis 
of the comparative time points), exhibited by increased antibody levels in primary vaccinated cats 
compared to annual vaccinated cats (mixed-effects analysis). Samples from days 0, 14*, and 28† 
post-final vaccination were compared (Primary: days 0, 70* and 84†; Annual: days 0, 14*, and 28†). 
Negative fold (NF) = (sample MFI) / (2 × negative control MFI). OD = optical density. * = p < 0.05, 
**** = p < 0.0001. 
3.5. Antibodies to FIV gp40 with ELISA Testing 
Results from ELISA testing of plasma samples from days 0, 14*, and 28† after final 
vaccination (Primary: days 0, 70* and 84†; Annual: days 0, 14* and 28†) to detect anti-gp40 
antibodies are presented in Figure 2 and Supplementary Table S2. Similar to FIV p24, anti-
gp40 antibody levels increased significantly over time in both primary and annual FIV 
vaccinated animals (Primary: p = 0.024; Annual: p = 0.0022), and the overall magnitude of 
the anti-gp40 antibody response in the primary vaccination group was 3.0× higher at day 
14* and 2.3× higher at day 28† compared to the annual vaccination group (treatment, p < 
0.0001) (mixed-effects analysis). Levels of anti-gp40 antibodies increased significantly in 
primary vaccinated cats over the course of this study (interaction, p < 0.0001) and at indi-
vidual time points (day 14*: p < 0.001; day 28†: p = 0.012) compared to the annual vac-
cinated animals (mixed-effects analysis). Anti-gp40 antibodies were detected by ELISA in 
4/10 cats in the annual vaccination group on day 0, indicating that antibodies persisted 
for at least 12 months after previous vaccination in a subset of cats (Table 4), despite all 
10 cats testing negative with Witness® and Anigen Rapid® PoC kits on day 0. Regardless 
of the persistence of anti-gp40 antibodies in some cats for 12 months, post hoc analysis 
revealed there was no significant difference between anti-gp40 antibody levels in primary 
vs. annually vaccinated cats on day 0 (p = 0.56, Šídák’s multiple comparisons test). 
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When anti-gp40 ELISA results from the primary FIV vaccination cohort were com-
pared with results from the two anti-gp40 PoC kits (Witness® and Anigen Rapid®), a sig-
nificant correlation was observed (p < 0.0001), with some overlap (Supplementary Table 
S3). Specifically, increased levels of anti-gp40 antibodies in primary vaccinated cats were 
strongly associated with the likelihood of a false-positive PoC test result (Witness® odds 
ratio [OR]: 1.46, p < 0.0001; Anigen Rapid® OR: 1.25, p < 0.0001), such that 1 unit increase 
in anti-gp40 NF was associated with 46% increased likelihood of Witness® testing false-
positive and 25% increased likelihood of Anigen Rapid® testing false-positive. Negative 
results with Witness® had a range of NF values from 1.0 to 17.2 (median 2.9), while false-
positive results with Witness® ranged from 4.0 to 25.5 (median 17.3). Negative results with 
Anigen Rapid® had a range of NF values from 1.0 to 20.5 (median 3.6), while false-positive 
results with Anigen Rapid® ranged from 4.1 to 25.5 (median 16.6). 
 
Figure 2. Primary FIV vaccination also induced a higher anti-gp40 antibody response than annual 
FIV re-vaccination. Anti-gp40 antibodies increased significantly over time in both primary and 
annual vaccination groups (Primary: p = 0.024; Annual: p = 0.0022; blue and red bars below the box 
plots, respectively; mixed-effects analysis). Anti-gp40 antibodies differed significantly over time 
between groups (interaction, p < 0.0001) and at individual time points following vaccination (day 
14*: p < 0.001; day 28†: p = 0.012, where the black bars joining the box plots indicate the analysis of 
the comparative time points), with primary vaccination inducing higher levels of antibodies com-
pared to annual vaccination (mixed-effects analysis). Samples from days 0, 14*, and 28† post-final 
vaccination were compared (Primary: days 0, 70* and 84†; Annual: days 0, 14*, and 28†). NF = 
(sample OD) / (2 × negative control OD). OD = optical density. * = p < 0.05, *** = p < 0.001. 
3.6. Comparing anti-p24 and anti-gp40 Antibody Responses to Number of Annual FIV 
Vaccinations 
Multivariate logistic regression revealed a trend where the number of annual FIV 
vaccinations correlated with the detection of anti-p24 antibodies (p = 0.076) at 12 months 
post-vaccination (i.e., day 0 in the annual vaccination group) (Table 4). 
Cats with higher numbers of annual FIV vaccinations were not more likely to test 
positive for anti-gp40-antibodies (p = 0.23; multivariate logistic regression) (Table 4). 
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Table 4. Cats that received a higher number of annual FIV re-vaccinations were more likely to have antibodies against 
p24 12 months post-vaccination. In total, 6/10 and 4/10 cats in the annual vaccination group tested positive on day 0 for 
antibodies against p24 and gp40, respectively, demonstrating that these cats had a duration of antibody response of at 
least 12 months since their last FIV vaccination. Cats administered a higher number of annual FIV vaccinations were more 
likely to test positive for anti-p24 antibodies at 12 months post-vaccination (p = 0.076; multivariate logistic regression). 
There was no trend observed with anti-gp40 antibody ELISA results at 12 months in cats administered a higher number 
of annual FIV vaccinations (p = 0.23; multivariate logistic regression). Samples were considered antibody positive if NF 
values were greater than the mean NF of FIV-unvaccinated controls × 2 standard deviations. NF = negative fold, MIA = 
microsphere immunoassay testing, and ELISA = laboratory-based anti-FIV transmembrane peptide ELISA testing. 
Anti-p24 Antibodies (MIA)  
12 Months Post-Vaccination 
Anti-gp40 Antibodies (ELISA)  
12 Months Post-Vaccination 
No. of Annual FIV Vaccinations  
(Prior to Enrollment) 
− − 0 
− + 1 
+ − 1 
− − 2 
+ − 2 
+ − 2 
− + 2 
+ + 2 
+ − 3 
+ + 7 
6/10 cats 4/10 cats  
4. Discussion 
Results from the present study demonstrated that both vaccination protocols with 
Fel-O-Vax® FIV–three primary vaccinations four weeks apart, and a single annual re-vac-
cination–induced a measurable vaccine-specific antibody response against FIV capsid 
protein p24 with a laboratory-based MIA, and against gp40 with a laboratory-based trans-
membrane peptide ELISA and PoC testing. The magnitude of antibody production over 
time was conspicuously greater in the primary FIV vaccination group compared to the 
annual FIV vaccination group for both antibodies assayed with laboratory-based tests. 
This difference between vaccination groups for anti-gp40 antibodies as measured by 
ELISA was consistent with results from Witness® and Anigen Rapid® FIV PoC testing [21], 
with some false-positive results seen in the primary FIV vaccination cohort from day 14 
(two weeks after first primary FIV vaccination) until day 84 (four weeks after final pri-
mary FIV vaccination), but not in the annual FIV vaccination cohort. Consequently, Wit-
ness® and Anigen Rapid® kits are ideal for use in cats that have received an annual FIV 
re-vaccination within the preceding 12 months, irrespective of how recently the annual 
vaccination was given.  
SNAP® Combo produced false-positive results in all cats from both the primary and 
annual vaccination groups, and therefore this kit cannot be used to distinguish FIV-vac-
cinated/FIV-uninfected cats from FIV-infected cats. If a positive FIV result is obtained 
with SNAP® Combo in a cat with a possible history of FIV vaccination, follow-up testing 
(e.g., testing with Witness®, Anigen Rapid®, or the slightly less sensitive FIV RealPCRTM) 
should be pursued [11]. Since antibodies against FIV matrix protein p15 were not meas-
ured, we were unable to determine whether the false-positive results recorded with 
SNAP® Combo were due to the detection of vaccine-induced anti-p15 antibodies, anti-p24 
antibodies, or anti-gp40 antibodies (annual vaccination only).  
Using MIA and ELISA testing, antibodies against both p24 and gp40, respectively, 
were detectable on day 0 in a proportion of cats recruited for the annual vaccination study 
(6/10 and 4/10, respectively). This result demonstrated that anti-FIV antibodies induced 
by annual Fel-O-Vax® FIV vaccination may persist for 12 months or more, consistent with 
previous reports [33–35]. Interestingly, in the present study only 2/6 cats that tested posi-
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tive for anti-p24 antibodies on day 0 were also positive for anti-gp40 antibodies, suggest-
ing that some cats had a stronger immunological response to vaccine p24 than vaccine 
gp40, or vice versa. Following a single annual FIV vaccination, antibody levels to both 
p24 and gp40 increased significantly over time, with peak antibody levels occurring 2–4 
weeks after annual re-vaccination. Indeed, antibody levels were still increased at the final 
sampling (7/7 and 6/7 cats tested positive for anti-p24 and anti-gp40 antibodies, respec-
tively, on day 42 with the laboratory-based assays; Supplementary Table S4). Although 
peak antibody levels induced by annual FIV vaccination were lower than following pri-
mary FIV vaccination, this finding does not necessarily suggest that vaccine-induced im-
munity from annual FIV vaccination is poorer than primary FIV vaccination. Humoral 
(antibody-mediated; Th2) immunity has been shown to be important for homologous FIV 
challenge, but cell-mediated (Th1) immunity is likely more critical for protection against 
FIV than humoral immunity, in particular for heterologous (e.g., field virus) challenge 
[1,7,14,15,36–38]. For example, one study reported that 84% of vaccinates were protected 
from heterologous FIV challenge 12 months after a primary course of Fel-O-Vax® FIV vac-
cinations (three injections three weeks apart), despite anti-p24 antibody levels declining 
sharply by about three months following the third primary FIV vaccination [33].  
Factors that may have contributed to the reduced humoral response against both p24 
and gp40 following annual FIV re-vaccination compared to primary FIV vaccination in-
clude patient age, the number of FIV vaccines administered, and the re-vaccination inter-
val. Cats in the annual vaccination group were significantly older than the cats in the 
primary vaccination group, and these older cats may have had a reduced antibody pro-
duction potential. Flow cytometry studies have demonstrated an absolute reduction in T 
cells, B cells and natural killer cells in senior cats (10–14 years) compared to adult cats (2–
5 years) [39]. Furthermore, an age-related gradual decline in relative percentage of lym-
phocytes has been observed, with analysis of the CD4+/CD8+ ratio defining two statisti-
cally distinct age groups (<8 months and >8 months of age) [40]. Future studies could 
examine the possible effect of age on immunological response to FIV vaccination by re-
cruiting age-matched groups for primary and annual vaccination, and comparing the an-
tibody responses between the groups by age. Such a study would likely need to be labor-
atory-based since administering a primary course of FIV vaccines to older cats is relatively 
uncommon in clinical practice in Australia, with primary vaccination usually occurring 
in kittens. Therefore, this was beyond the scope of the present field study. The number of 
FIV vaccines administered was likely also a factor, i.e., the ‘booster’ effect of three doses 
(primary vaccination) vs. one (annual vaccination). Peak antibody levels for both antibod-
ies assayed in the primary vaccination group occurred two weeks after the second pri-
mary vaccination and maintained peak levels until two weeks after the third primary vac-
cination (i.e., day 42–day 70), demonstrating the booster effect of the second and third 
primary FIV vaccines (Supplementary Table S4). In elderly human subjects administered 
a single dose of an inactivated influenza vaccine, or two vaccine doses 12 weeks apart, 
booster vaccination yielded 14% higher post-vaccination titres than single vaccination 
[41]. Results of any vaccination regime is antigen and formulation dependent [42–44], and 
the immunological effects of changing the Fel-O-Vax® FIV dosing schedule could be in-
vestigated. For example, trialing the administration of a second, or third, FIV dose as part 
of the annual re-vaccination schedule within a similar timeframe (i.e., 2–4 weeks apart), 
or reducing the annual re-vaccination interval (6 monthly rather than annually). The 
booster effect seen with multiple vaccines given within a short time frame likely relates 
to enhanced activation of the Th2 pathway, and as a result higher antibody titres, com-
pared to the Th1-dominated response that occurs with a single dose program [45]. 
Finally, it is possible in the present study that residual anti-FIV antibodies in cats 
administered an annual vaccination neutralized some of the vaccine antigen, thereby ef-
fectively reducing the dose of vaccine antigen received, and therefore also reducing the 
magnitude of the antibody response induced by annual re-vaccination compared to pri-
mary vaccination. This has been shown to occur with FPV vaccination [46]. Similarly, a 
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reduced antibody response following vaccination can result from the presence of mater-
nally-derived antibodies (MDA). In kittens administered an inactivated vaccine against 
FHV-1 and FCV, vaccination was found to be more effective in the presence of low MDA 
than high MDA, as measured by virus neutralization to determine the proportion of kit-
tens with protective antibody titres against FHV-1 and FCV [47]. In the present study, no 
difference in the magnitude of the anti-p24 or anti-gp40 antibody response was observed 
in the annual vaccination group according to the presence or absence of anti-p24 and anti-
gp40 antibodies, respectively, on day 0 (Supplementary Table S5). For this reason, in fu-
ture studies, it would be interesting to trial both shorter and longer re-vaccination inter-
vals after the three-dose primary FIV vaccination schedule to determine the effect on post-
vaccinal antibody response. 
5. Conclusions 
Despite the advent of molecular testing, detection of antibodies against FIV remains 
the most sensitive method for diagnosing FIV infection. Many FIV PoC antibody test kits 
are available around the world and they vary with regards to methodology (e.g., immu-
nochromatography vs. ELISA), and choice of capture antigen used (e.g., p15, p24 and TM 
peptide), which in turn affects their accuracy. Differences in test kit performance are par-
ticularly pronounced in FIV-vaccinated cats. In countries where vaccination with Fel-O-
Vax® FIV is practiced, Witness® and Anigen Rapid® can be reliably used to diagnose FIV 
infection in cats administered a primary course of FIV vaccination more than six months 
prior to testing, and in any cats administered an annual FIV vaccination, irrespective of 
how recently it was administered. If FIV testing is required in a cat that has recently com-
menced or completed a primary course of FIV vaccination, a sensitive PCR assay should 
be used (e.g., FIV RealPCRTM), or if available, virus isolation. Investigation of the antibody 
response in cats vaccinated against FIV enhances our general understanding of vaccine-
induced Th1 and Th2 responses, and differences that may occur depending on the length 
of the re-vaccination interval, which may be important for the development of other vac-
cines and dosing schedules. 
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